209 related articles for article (PubMed ID: 37764297)
21. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
22. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
23. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
24. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
[No Abstract] [Full Text] [Related]
25. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
27. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
[TBL] [Abstract][Full Text] [Related]
28. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
29. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
30. Novel Coumarin-furo[2,3-d]pyrimidinone hybrid derivatives as anticancer agents: Synthesis, biological evaluation and molecular docking.
Jin Y; He S; Wu F; Luo C; Ma J; Hu Y
Eur J Pharm Sci; 2023 Sep; 188():106520. PubMed ID: 37423580
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, biological evaluation, and molecular modeling studies of acetophenones-tethered 1,2,4-triazoles and their oximes as epidermal growth factor receptor inhibitors.
El-Wahab HAAA; Ali AM; Abdel-Rahman HM; Qayed WS
Chem Biol Drug Des; 2022 Dec; 100(6):981-993. PubMed ID: 34773452
[TBL] [Abstract][Full Text] [Related]
36. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
37. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
Warda ET; Shehata IA; El-Ashmawy MB; El-Gohary NS
Bioorg Med Chem; 2020 Nov; 28(21):115674. PubMed ID: 33065442
[TBL] [Abstract][Full Text] [Related]
38. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF
Abou-Zied HA; Beshr EAM; Gomaa HAM; Mostafa YA; Youssif BGM; Hayallah AM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200464. PubMed ID: 36526595
[TBL] [Abstract][Full Text] [Related]
39. Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship.
Hassan OM; Kubba A; Tahtamouni LH
Anticancer Agents Med Chem; 2023; 23(11):1336-1348. PubMed ID: 36847231
[TBL] [Abstract][Full Text] [Related]
40. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]